Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07283263 | A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986521 in Healthy Participants. | PHASE1 | RECRUITING | 106 | — | — | Dec 23, 2025 | Nov 17, 2026 | Jan 7, 2026 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| Part A Cohort 1 | EXPERIMENTAL | - |
| Part A Cohort 2 | EXPERIMENTAL | - |
| Part A Cohort 3 | EXPERIMENTAL | - |
| Part A Cohort 4 | EXPERIMENTAL | - |
| Part A Cohort 5 | EXPERIMENTAL | - |
| Part A Cohort 6 | EXPERIMENTAL | - |
| Part B Cohort 7 | EXPERIMENTAL | - |
| Part B Cohort 8 | EXPERIMENTAL | - |
| Part B Cohort 9 | EXPERIMENTAL | - |
| Part B Cohort 10 | EXPERIMENTAL | - |
| Part B Cohort 11 | EXPERIMENTAL | - |
| Part C | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-985521 | DRUG | Specified dose on specified days. |
| Placebo | OTHER | Specified dose on specified days |
Inclusion Criteria: * Participants must be healthy males and females (assigned at birth) who are not of childbearing potential, with no clinically significant abnormalities in medical history, physical exam, ECG, or lab tests. * Participants must have a body mass index (BMI) between 18 and 32 kg/m²...